Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study

Journal of the American Academy of Dermatology

Volumn 73, Issue 2, 2015, Pages 331-333.e1

  Dogra, Sunil ^a   D s , Krupashankar ^b   Budamakuntla, Leelavathy ^c   Srinivas, C R ^d   Khopkar, Uday ^e   Gupta, Sandesh ^f   Shetty, Narendra ^g   Pratap, Dasiga Venkata Subrahmanya ^h   Gopal, M G ⁱ   Rao, T Narayana ^j   Garg, Vijay ^k   Sumathy, T K ^l   Saraswat, Abir ^m   Bhat, Ramesh ⁿ   Kura, Mahendra ^o   Pandey, Neeraj ^p   Shah, Radha ^q   Sai Krishna, Kotla ^r   Padmaja, Dalavai ^s   Manmohan, G ^t   M s , Ramakrishnan ^u   Barve, Abhijit ^u   Montero, Enrique ^u,v   more..

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b MANIPAL HOSPITAL   (India)

^c Bowring and Lady Curzon Hospitals   (India)

^d Department of Fashion Technology   (India)

^e KEM HOSPITAL   (India)

^f Skin Laser Center   (India)

^g A J INSTITUTE OF MEDICAL SCIENCES   (India)

^h Department of Cardiology   (India)

ⁱ KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^j King George Hospital   (India)

^k LOK NAYAK HOSPITAL   (India)

^l M S RAMAIAH UNIVERSITY OF APPLIED SCIENCES   (India)

^m Indushree Skin Clinic   (India)

ⁿ FATHER MULLER MEDICAL COLLEGE   (India)

^o SIR J J GROUP OF HOSPITALS   (India)

^p Laser and Cosmetic Clinic   (India)

^q APOLLO HOSPITAL   (India)

^r Sri Sai Skin Clinic   (India)

^s Sumana Hospital   (India)

^t Derma Skin Clinic   (India)

^u Biocon Research Limited   (India)

^v CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ITOLIZUMAB; MONOCLONAL ANTIBODY;

CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84937442023     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.03.040     Document Type: Article

References (5)

1. D.S. Krupashankar, S. Dogra, M. Kura, and et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study J Am Acad Dermatol 71 2014 484 492
2. R. Alonso, V. Huerta, J. de Leon, and et al. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody Hybridoma (Larchmt) 27 2008 291 301
3. C.S. Carlin, S.R. Feldman, J.G. Krueger, A. Menter, and G.G. Krueger A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866
4. A. Kim The long-term efficacy and safety of new biological therapies for psoriasis Arch Dermatol Res 298 2006 7 15
5. P. Nair, R. Melarkode, D. Rajkumar, and E. Montero CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction Clin Exp Immunol 162 2010 116 130